SCHEMBL3597265

SCHEMBL3597265

Clc1ccc(Nc2cnc(Nc3cccc(OCc4ccccc4)c3)nc2)cc1Cl

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 1/20 0.48
CTSV O60911 1/20 0.48
CTSL P07711 1/20 0.48
PTK6 Q13882 1/20 0.47
SIRT2 Q8IXJ6 1/20 0.46
DYRK1B Q9Y463 2/20 0.45
DYRK1A Q13627 1/20 0.45
CTSC P53634 1/20 0.44
GRK2 P25098 1/20 0.44
GRK5 P34947 1/20 0.44
GRK3 P35626 1/20 0.44
ULK1 O75385 1/20 0.44
MAPK1 P28482 1/20 0.44
KDM4E B2RXH2 1/20 0.43
MEN1 O00255 1/20 0.43
ALDH1A1 P00352 1/20 0.43
GAA P10253 1/20 0.43
MAPT P10636 1/20 0.43
THRB P10828 1/20 0.43
PKM P14618 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3594258 0.90 CTSV (0.56) SYKCTSVCTSLPTK6SIRT2
SCHEMBL14379768 0.81 CTSV (0.53) SYKCTSVCTSLPTK6SIRT2
SCHEMBL3586436 0.81 MAOB (0.57) SYKCTSVCTSLPTK6SIRT2
SCHEMBL3605467 0.81 PIK3CA (0.60) SYKMAPK1MEN1MAPTRAB9A
SCHEMBL3594864 0.80 IDH2 (0.53) SYKCTSVCTSLPTK6SIRT2
SCHEMBL6359813 0.79 CTSV (0.56) CTSVCTSLPTK6SIRT2MAPK1
SCHEMBL6098127 0.79 CTSV (0.65) SYKCTSVCTSLPTK6SIRT2
SCHEMBL3591877 0.78 HDAC6 (0.53) SYKDYRK1AHDAC3HDAC1HDAC2
SCHEMBL6355348 0.78 CTSV (0.58) CTSVCTSLPTK6SIRT2KDM4E
SCHEMBL3589681 0.76 SYK (0.48) SYKCTSVCTSLPTK6SIRT2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130059871-A1 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES HORWELL DAVID CHRISTOPHER (GB) 2013-03-07 US disclosed
US-20100063077-A1 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES SENEXIS LIMITED (GB) 2010-03-11 US disclosed
EP-2010502-A1 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES Senexis Limited (GB) 2009-01-07 EP disclosed
WO-2007125351-A1 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES SENEXIS LIMITED (GB) 2007-11-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100063077-A1 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES TYMP, APP, HTT SYK 3311/4885CTSV 2095/4885CTSL 3733/4885
US-20130059871-A1 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES TYMP, APP, HTT SYK 3311/4885CTSV 2095/4885CTSL 3733/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.